共 50 条
- [21] Reduced-Intensity Chemotherapy with Mini-Hyper-CVD Plus Inotuzumab Ozogamicin, with or without Blinatumomab, in Older Adults with Newly Diagnosed Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: Results from a Phase II StudyBLOOD, 2020, 136Short, Nicholas J.Kantarjian, Hagop M.Ravandi, FarhadHuang, XuelinJain, NitinKadia, Tapan M.Khoury, Joseph D.Jorgensen, Jeffrey L.Wang, Sa A.Alvarado, YesidBurger, Jan A.Daver, NavalBorthakur, GautamDiNardo, Courtney D.Konopleva, MarinaPemmaraju, NaveenGarcia-Manero, GuillermoWierda, William G.Kornblau, Steven M.Jacob, JovittaRostykus, MeaganKwari, MonicaRausch, Caitlin R.Loiselle, ChristopherMilton, AnnaRivera, JuanGarris, RebeccaO'Brien, Susan M.Jabbour, Elias
- [22] Inotuzumab ozogamicin (IO) combined with mini-hyper-CVD as salvage therapy for patients (pts) with R/R acute lymphoblastic leukemia (ALL).JOURNAL OF CLINICAL ONCOLOGY, 2017, 35Assi, RitaKantarjian, Hagop M.Ravandi, FarhadO'Brien, Susan MaryKebriaei, PartowThomas, Deborah A.Garcia-Manero, GuillermoKhouri, Issa F.Champlin, Richard E.Kadia, Tapan M.Cortes, Jorge E.Jain, NitinKonopleva, MarinaKhouri, RitaEstrov, ZeevTakahashi, KoichiSasaki, KojiJacob, JovittaGarris, RebeccaJabbour, Elias
- [23] Chemoimmunotherapy with Inotuzumab Ozogamicin Combined with Mini-Hyper-CVD, with or without Blinatumomab, for Newly Diagnosed Older Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: Results from a Phase II StudyBLOOD, 2018, 132Short, Nicholas J.Jabbour, Elias J.Ravandi, FarhadHuang, XuelinJain, NitinSasaki, KojiPemmaraju, NaveenDaver, Naval G.Khoury, Joseph DavidJorgensen, Jeffrey L.Alvarado, YesidKonopleva, Marina Y.Garcia-Manero, GuillermoKadia, Tapan M.Yilmaz, MusaBorthakur, GautamBurger, Jan A.Kornblau, Steven M.Wierda, William G.DiNardo, Courtney D.Ferrajoli, AlessandraNasnas, PatriceJacob, JovittaGarris, Rebecca E.O'Brien, Susan M.Kantarjian, Hagop M.
- [24] Updated Results of the Combination of Mini-Hyper-CVD with Inotuzumab Ozogamicin and Blinatumomab in Patients with Relapsed/Refractory B-Cell ALLBLOOD, 2024, 144 : 2811 - 2812Habib, DianeKantarjian, Hagop M.Haddad, Fadi G.Short, Nicholas J.Jain, NitinSenapati, JayastuChien, Kelly S.Garcia-Manero, GuillermoKomrokji, ZenaKadia, Tapan M.Daver, NavalDinardo, Courtney D.Sasaki, KojiGarris, RebeccaRavandi, FarhadJabbour, Elias
- [25] Salvage Chemotherapy with Inotuzumab Ozogamicin (INO) Combined with Mini-Hyper-CVD for Adult Patients with Relapsed/Refractory (R/R) Acute Lymphoblastic Leukemia (ALL)BLOOD, 2015, 126 (23)Sasaki, KojiKantarjian, Hagop M.O'Brien, SusanThomas, Deborah A.Ravandi, FarhadGarcia-Manero, GuillermoKadia, TapanJain, NitinKonopleva, MarinaEstrov, ZeevTakahashi, KoichiKhouri, Maria R.Jacob, JovittaGarris, RebeccaCortes, Jorge E.Jabbour, Elias
- [26] Impact of Cytogenetic Abnormalities (CA) on Outcome of Patients (Pts) with Relapsed/Refractory (R-R) Acute Lymphoblastic Leukemia (ALL) Treated with Inotuzumab Ozogamicin (INO) in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) with or without Blinatumomab: Results from a Phase 2 StudyBLOOD, 2020, 136Rafei, HindKantarjian, Hagop M.Sasaki, KojiShort, Nicholas J.Ravandi, FarhadHuang, XuelinKhoury, Joseph D.Wang, Sa A.Jorgensen, Jeffrey L.Yin, C. CameronKhouri, Issa F.Kebriaei, PartowJain, NitinTakahashi, KoichiDabaja, Bouthaina S.Verstovsek, SrdanKadia, Tapan M.Paul, ShilpaRausch, Caitlin R.Garcia-Manero, GuillermoWierda, William G.DiNardo, Courtney D.Daver, NavalMontalban-Bravo, GuillermoYilmaz, MusaNasnas, PatriceKhouri, RitaKwari, MonicaJacob, JovittaRostykus, MeaganGarris, RebeccaKonopleva, MarinaO'Brien, Susan M.Jabbour, Elias
- [27] Updated Results from a Phase II Study of Mini-Hyper-CVD Plus Inotuzumab Ozogamicin, with or without Blinatumomab, in Older Adults with Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic LeukemiaBLOOD, 2021, 138Short, Nicholas J.Kantarjian, HagopRavandi, FarhadHuang, XuelinJain, NitinKadia, Tapan M.Khoury, Joseph D.Jorgensen, Jeffrey L.Wang, Sa A.Alvarado, YesidBurger, Jan A.Daver, NavalBorthakur, GautamDiNardo, Courtney D.Konopleva, MarinaPemmaraju, NaveenGarcia-Manero, GuillermoWierda, William G.Kornblau, Steven M.Jacob, JovittaKwari, MonicaRausch, Caitlin R.Loiselle, ChristopherMilton, AnnaRivera, JuanGarris, RebeccaO'Brien, Susan M.Jabbour, Elias J.
- [28] Updated Results of the Phase II Trial of Inotuzumab Ozogamicin (INO) Combined with Mini-Hyper-CVD As Salvage Therapy for Relapsed/Refractory (R/R) B-Cell Acute Lymphoblastic Leukemia (B-ALL)BLOOD, 2017, 130Assi, RitaKantarjian, Hagop M.Khouri, RitaRavandi, FarhadKebriaei, PartowShort, Nicholas J.Thomas, Deborah A.Garcia-Manero, GuillermoChamplin, Richard E.Kadia, TapanCortes, Jorge E.Jain, NitinKonopleva, MarinaEstrov, ZeevTakahashi, KoichiSasaki, KojiJacob, JovittaManzoor, AmeenaGarris, RebeccaO'Brien, Susan M.Jabbour, Elias J.
- [29] A Phase II Study of the Sequential Combination of Low-Intensity Chemotherapy (mini-hyper-CVD) and Ponatinib Followed By Blinatumomab and Ponatinib in Patients with Philadelphia Chromosome-Positive (Ph plus ) Acute Lymphoblastic Leukemia (ALL)BLOOD, 2022, 140 : 6127 - 6129Nguyen, DanielJabbour, EliasShort, NicholasIssa, Ghayas C.Yilmaz, MusaDaver, NavalPemmaraju, NaveenChien, Kelly S.Masarova, LuciaRavandi, FarhadJain, NitinDeen, WuliamatuZhao, MinLoiselle, ChristopherWaller, LourdesBanks, GlendaGarris, RebeccaKantarjian, Hagop
- [30] A Phase II Study of Mini-Hyper-CVD Plus Inotuzumab Ozogamicin, with or without Blinatumomab, in Older Adults with Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia: Updated Results and Predictors for OutcomesBLOOD, 2022, 140 : 11679 - 11682Nasnas, PatriceJabbour, EliasShort, NicholasRavandi, FarhadHuang, XuelinJain, NitinKadia, Tapan M.Alvarado, YesidBurger, Jan A.Daver, NavalBorthakur, GautamDiNardo, Courtney D.Konopleva, MarinaGarcia-Manero, GuillermoWierda, William G.Jacob, JovittaDeen, WuliamatuKwari, MonicaLoiselle, ChristopherRoy, EdithMilton, AnnaRivera, JuanGarris, RebeccaKantarjian, Hagop